Dnage

DOCKET NO.: 2719.2004-000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

March 17, 2004

Stephen P.A. Fodor, J. Leighton Read, Lubert Stryer, Michael C. Pirrung

Application No.: 09/653,761

Group Art Unit: 1639

Filed:

September 1, 2000

Examiner:

Ponnaluri, Padmashri

Confirmation No.: 6146

Title:

POLYPEPTIDE ARRAYS

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This	Information	Disclosure	Statement i	s submitted
11112	HIIOHHAMOH	Dipologare	C 100 1 2 1	

under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either: [X]

a Statement under 37 CFR 1.97(e), as checked below, or []

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with: []

[]

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[X] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

[] a Statement under 37 CFR 1.97(e), as checked below, and

[] a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Stater	ment Und	ler 37 CFR 1.97(e)
[]		em of information contained in this Information Disclosure Statement was first cited in munication from a foreign patent office in a counterpart foreign application not more ree months prior to the filing of this Information Disclosure Statement; or
[]	commu knowle	n of information contained in this Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart foreign application, and, to the edge of the undersigned, after making reasonable inquiry, no item of information contained information disclosure statement was known to any individual designated in 37 CFR more than three months prior to the filing of this Information Disclosure Statement.
State	ment Unc	der 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000
[]	comm	tem of information contained in the Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart application and this communication of treceived by any individual designated in § 1.56(c) more than thirty days prior to the of the Information Disclosure Statement.
[X]	Enclos	sed herewith is form PTO-1449:
	[X]	Copies of the cited references are enclosed.
		[] Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
	[]	Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
	[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
	[]	The "concise explanation" requirement (non-English references) for reference(s) [under 37 CFR 1.98(a)(3) is satisfied by:
		[] the explanation provided on the attached sheet.
		[] the explanation provided in the Specification.
		[] submission of the enclosed International Search Report.
•		[] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
_		[] the enclosed English language abstract.

[]	Applic	cant requests that the following n	on-published pending applic	eations be considered:
Examiner's Initials				
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
		Examiner	Date	_
	[]	A copy of each above-cited app	olication, including the curre	nt claims, is enclosed.
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	olication, including the curre on, U.S. Application No. [nt claims, is enclosed, except], to which priority under
The E	xamine nces we	r is requested to return a copy of reconsidered with the next office	the above list of pending ap e communication.	plications indicating which
It is re	queste	I that the information disclosed h	nerein be made of record in t	his application.
Metho	od of pa	syment:		
[X]	A che accon	ck for the fee noted above is encorpanying Reply. A copy of this S	losed, or the fee has been inc Statement is enclosed.	cluded in the check with the
[]	Please	e charge Deposit Account 08-038 sed.	30 in the amount of \$[]. A copy of this Statement is
[X]	Pleas	e charge any deficiency in fees ar	nd credit any overpayment to	Deposit Account 08-0380.

REMARKS

The current Supplemental IDS incorporates references that have been disclosed in recent litigation.

Additionally, Applicants would like to notify the Examiner of inter party matters that relate to the present application. Two commonly owned patents US 5,744,305 and US 5,800,992 have been involved in interference proceedings. Specifically, the interferences were Interference No. 104,359 between commonly owned US 5,744,305 and Brown et al., USSN 08/688,488, and Interference No. 104,358 between commonly owned US 5,800,992 and USSN 08/514,875. Both interferences have been decided

(subject to current appeal in District Court of Northern California, Civil Case No. C99 21111-JF/EAI) by the USPTO in favor of real party in interest Affymetrix, the assignee of the present application. The Junior party challenged the patents on the basis of lack of enablement and written description under 35 USC §112, among other issues. The Junior party's initial position is set out in papers (with supporting information) entitled "Request for Declaration of Interference, 37 C.F.R. §1.608" in both interferences. The initial response of Senior party Patentee is set out in papers (with supporting information) entitled "Fodor's Opposition to Brown's Rule 608(b) Request" in both interferences.

Further, US 5,744,305, US 5,445,934 and US 5,800,992 have been the subject of litigation (Affymetrix, Inc. v. Hyseq, Inc., US District Court for the Northern District of California, San Francisco Division, Civil Action No. C98-03192 FMS, and Affymetrix. v. Synteni, Inc. and Incyte Pharmaceuticals, Inc., US District Court for the Northern District of California, San Francisco, Case No. C98-4508 FMS (MEJ)). In the course of these proceedings, allegations of invalidity over prior art, lack of enablement, lack of support and inequitable conduct (relating to duty of candor, content of declarations under 37 CR §1.132, and arguments made during prosecution) were raised. These allegations were denied. In a more recent lawsuit with Incyte Genomics (Incyte Genomics Inc. v. Affymetrix, U.S. District Court, Northern district of California, San Francisco division and is Case No. C 00-3210 JF.), Affymetrix counterclaimed for patent infringement under U.S. patent 5,871,928 ('928) and 6,040,193. Incyte has filed their "Initial Disclosure of Prior Art" and the references cited therein have been included into the current IDS.

All of the above lawsuits have been settled. Prior to settlement, there was a Markman decision regarding the '305 and '934 patents but no decision on the merits. In the '992 patent, the court held that the claim term "substantially complementary" was indefinite and there was lack of written description for the word "mixture" in the claims of the '992 patent. No substantive decisions were made in the lawsuit involving the '928 and '193 patents.

Further, oppositions have been filed against a related European application EP 619,321 in the European Patent Office, and a revocation proceeding was brought in the United Kingdom against related patents GB 2,248,840 and EP (UK) 0619 321. Applicants can provide copies of litigation documents that may be of interest to the Examiner, but have not done so due to the extensive nature of the multiple litigation and papers filed therein. The revocation proceedings have been settled without any decision on the merits.

Applicants also wish to identify two other interferences that were declared and settled between applications that are related to the present application. The application serial number is 09/063,933 and the interference is declared with U.S. Patent No. 6,054,270 (E. Southern). One interference 104,658 has been settled with priority for certain claims to Southern. However, other claims not corresponding to the interference count have been allowed to applicants from the '933 application. The second interference involves application serial number USSN 09/614,068 and the interference was declared with U.S. Patent Nos. 5,922,534 (K. Lichtenwalter) and 6,255,053 (K. Lichtenwalter). The Interference Number was 105,089, but it has subsequently been terminated due to a motion of patent invalidity based on prior art.

Both Agilent patents were invalidated and the Affymetrix claims that were copied from the two patents were declared unpatentable.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Jesse A. Fecker Registration No.: 52,883 Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

1639

PTO-1449	REPRODUCED
نز	SUPPLEMENTAL INFORMATION DISCLOSURE CTATION IN AN APPLICATION
	(Use several sheets if necessary)

				Sheet 1 of 2
	ATTORNEY DOCKET NO. 2719.2004-000	1	LICATION NO. 653,761	
1	FIRST NAMED INVENTOR Stephen P.A. Fodor	_	FILING DATE September	1, 2000
[B	EXAMINER	CONFI	RMATION NO.	GROUP

6146

		U.S	S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AE	3,642,450	02-15-1972	Eriksson
	AF	4,563,417	01-07-1986	Albarella et al.
	AG	4,996,142	02-26-1991	Al-Hakim et al.
	АН	5,171,534	12-15-1992	Smith et al.
	AK	5,242,794	09-07-1993	Whiteley et al.
	AJ	5,521,065	05-28-1996	Whiteley et al.
	AK	5,688,642	11-18-1997	Chrisey et al.
	AA2	5,744,101	04-28-1998	Fodor et al.
	AB2	5,753,788	05-19-1998	Fodor et al.
•	AC2	5,770,456	06-23-1998	Holmes
	AD2	5,837,832	11-17-1998	Chee et al.
	AE2	5,889,165	03-30-1999	Fodor et al.
	AF2	6,124,102	09-26-2000	Fodor et al.
	AG2	6,200,748 B1	03-13-2001	Smith et al.
	AH2	6,310,189 B1	10-30-2001	Fodor et al.
	AI2	6,329,143 B1	12-11-2001	Stryer et al.
	AJ2	6,346,413 B1	2-12-2002	Fodor et al.
	AK2	6,403,957 B1	6-11-2002	Fodor et al.
	AA3	6,406,844 B1	6-18-2001	Fodor et al.

P. Ponnaluri

	<u> </u>			
		OTHER DOCL	MENTS (Including Author, Title, Date, F	Pertinent Pages, Etc.)
Maskos, U., and Southern, E.M., "Parallel Analysis of Oligodeoxyribonucelotide (oligonucleotide) Interactions. I. Analysis of Factors Influencing Oligonucleotide Duplex Formation, Nucleic Acids Research, 20(7): 1675-1678 (1992).				
	AU	Wetmer, J.G., "Light-Direct Mol. Biol., 2: 207-210 (199		Chemical Synthesis," Chemtracts-Bioch

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2719.2004-000
SUPPLEMENTAL INFORMATION DISCLOSURE GUTATION IN AN APPLICATION	FIRST NAMED INVENTOR Stephen P.A. Fodor
January 29, 2004 (Use several sheets if necessary)	EXAMINER P. Ponnaluri
A TRADENT	

APPLICATION NO.
2719.2004-000

FIRST NAMED INVENTOR
Stephen P.A. Fodor

APPLICATION NO.
09/653,761

FILING DATE
September 1, 2000

AMINER CONFIRMATION NO. GROUP 1639

		A TRADE
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	AV	Chow, T., et al., "A High Capacity, Reusable Oligodeoxythimidine Affinity Column, Analytical Biochemistry, 175: 63-66 (1988).
	AW	Dunn, A.R., and Sambrook, J., "Mapping Viral mRNAs by Sandwich Hybridization, Methods in Enzymology, 65: 468-478 (1980).
	AX	Weetall, H.H., "Covalent Coupling Methods for Inorganic Support Materials, Methods in Enzymology, 44: 134-148 (1976).
	AY	Rentrop, M., et al., "Aminoakylsilane-treated Glass Slides as Support for in situ Hybridization of Keratin cDNAs to Frozen Tissue Sections Under Varying Fixation and Pretreatment Conditions, Histochemical Journal, 18: 271-276 (1986).
•	AZ	Matteucci, M.D. and Caruthers, M.H., "Synthesis of Deoxyoligonucleotides on a Polymer Support, J. Am. Chem. Soc., 103: 3185-3191 (1981).
	AR2	Kessler, "Nonradioactive Labeling Methods for Nucleic Acids," <i>Nonisotopic DNA Probe Techniques</i> , edited by Larry Kricka, Chapter 2, pp. 29-92 (1991).
	AS2	Dyson, N.J., "Immobilization of Nucleic Acids and Hybridization Analysis," Essential Molecular Biology Volume II: A Practical Approach, edited by T.A. Brown, Chapter 5, pp. 111-156 (1991).
	AT2	"Chapter 6: Chemistry for Automated DNA/RNA Synthesis," in Applied Biosystems Models 392 and 394 DNA/RNA Synthesizers: Users Manual Applied Biosystems, (1991).
	AU2	"Van Nostrand Reinhold: Encyclopedia of Chemistry (4th ed.)," pg. 366 (1984).
	AV2	Jonsson, et al., "Surface Immobilization Techniques in Combination with Ellipsometry," Methods in Enzymology, 137: 381-388 (1988).
•	AW2	Maniatis, et al., "Molecular Cloning A Laboratory Manual," pp. 313-315 and 326-328 (1982).
	AX2	Davis, et al., "Basic Methods in Molecular Biology," pgs. 62-65, 68 and 75-78 (1986).

BEST

EXAMINER DATE CONSIDERED